Neuropeptides in spinal cord injury

Comparative experimental models

Alan I. Faden, Thomas P. Jacobs, George P. Smith, Barth A Green, Justin A. Zivin

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The possible role of endogenous opioids in the pathophysiology of spinal cord injury was evaluated utilizing a variety of experimental models and species. In the cat, we have shown that β-endorphin-like immunoreactivity was increased in plasma following traumatic spinal injury; such injury was associated with a decrease in spinal cord blood flow (SCBF) which was reversed by the opiate receptor antagonist naloxone. Naloxone treatment also significantly improved functional neurological recovery after severe injury. Thyrotropin-releasing hormone (TRH), possibly through its "anti-endorphin" actions, was even more effective than naloxone in improving functional recovery in the cat. In a rat model, utilizing a similar trauma method, TRH proved superior to naloxone in improving SCBF after injury. In addition, naloxone at high doses attenuated the hindlimb paralysis produced by temporary aortic occlusion in the rabbit. The high doses of naloxone required to improve neurological function after spinal injury suggest that naloxone's actions, if opiate receptor mediated, may be mediated by non-μ receptors. Dynorphin, an endogenous opioid with a high affinity for the κ receptor, produced hindlimb paralysis following intrathecal administration in rats. Taken together, these findings suggest that endogenous opioids, possibly acting at κ receptors in the spinal cord, may serve as pathophysiological factors in spinal cord injury.

Original languageEnglish
Pages (from-to)631-634
Number of pages4
JournalPeptides
Volume4
Issue number5
DOIs
StatePublished - Jan 1 1983

Fingerprint

Naloxone
Neuropeptides
Spinal Cord Injuries
Theoretical Models
Opioid Analgesics
Endorphins
Spinal Injuries
Spinal Cord
Thyrotropin-Releasing Hormone
Wounds and Injuries
Opioid Receptors
Hindlimb
Fetal Blood
Paralysis
Rats
Cats
Blood
Dynorphins
Recovery
Rabbits

Keywords

  • Dynorphin
  • Endogenous opioids
  • Naloxone
  • Spinal cord injury
  • TRH

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Neuropeptides in spinal cord injury : Comparative experimental models. / Faden, Alan I.; Jacobs, Thomas P.; Smith, George P.; Green, Barth A; Zivin, Justin A.

In: Peptides, Vol. 4, No. 5, 01.01.1983, p. 631-634.

Research output: Contribution to journalArticle

Faden, Alan I. ; Jacobs, Thomas P. ; Smith, George P. ; Green, Barth A ; Zivin, Justin A. / Neuropeptides in spinal cord injury : Comparative experimental models. In: Peptides. 1983 ; Vol. 4, No. 5. pp. 631-634.
@article{04c8dc5e216641db87cb8251d85b6b44,
title = "Neuropeptides in spinal cord injury: Comparative experimental models",
abstract = "The possible role of endogenous opioids in the pathophysiology of spinal cord injury was evaluated utilizing a variety of experimental models and species. In the cat, we have shown that β-endorphin-like immunoreactivity was increased in plasma following traumatic spinal injury; such injury was associated with a decrease in spinal cord blood flow (SCBF) which was reversed by the opiate receptor antagonist naloxone. Naloxone treatment also significantly improved functional neurological recovery after severe injury. Thyrotropin-releasing hormone (TRH), possibly through its {"}anti-endorphin{"} actions, was even more effective than naloxone in improving functional recovery in the cat. In a rat model, utilizing a similar trauma method, TRH proved superior to naloxone in improving SCBF after injury. In addition, naloxone at high doses attenuated the hindlimb paralysis produced by temporary aortic occlusion in the rabbit. The high doses of naloxone required to improve neurological function after spinal injury suggest that naloxone's actions, if opiate receptor mediated, may be mediated by non-μ receptors. Dynorphin, an endogenous opioid with a high affinity for the κ receptor, produced hindlimb paralysis following intrathecal administration in rats. Taken together, these findings suggest that endogenous opioids, possibly acting at κ receptors in the spinal cord, may serve as pathophysiological factors in spinal cord injury.",
keywords = "Dynorphin, Endogenous opioids, Naloxone, Spinal cord injury, TRH",
author = "Faden, {Alan I.} and Jacobs, {Thomas P.} and Smith, {George P.} and Green, {Barth A} and Zivin, {Justin A.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0196-9781(83)90009-8",
language = "English",
volume = "4",
pages = "631--634",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Neuropeptides in spinal cord injury

T2 - Comparative experimental models

AU - Faden, Alan I.

AU - Jacobs, Thomas P.

AU - Smith, George P.

AU - Green, Barth A

AU - Zivin, Justin A.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - The possible role of endogenous opioids in the pathophysiology of spinal cord injury was evaluated utilizing a variety of experimental models and species. In the cat, we have shown that β-endorphin-like immunoreactivity was increased in plasma following traumatic spinal injury; such injury was associated with a decrease in spinal cord blood flow (SCBF) which was reversed by the opiate receptor antagonist naloxone. Naloxone treatment also significantly improved functional neurological recovery after severe injury. Thyrotropin-releasing hormone (TRH), possibly through its "anti-endorphin" actions, was even more effective than naloxone in improving functional recovery in the cat. In a rat model, utilizing a similar trauma method, TRH proved superior to naloxone in improving SCBF after injury. In addition, naloxone at high doses attenuated the hindlimb paralysis produced by temporary aortic occlusion in the rabbit. The high doses of naloxone required to improve neurological function after spinal injury suggest that naloxone's actions, if opiate receptor mediated, may be mediated by non-μ receptors. Dynorphin, an endogenous opioid with a high affinity for the κ receptor, produced hindlimb paralysis following intrathecal administration in rats. Taken together, these findings suggest that endogenous opioids, possibly acting at κ receptors in the spinal cord, may serve as pathophysiological factors in spinal cord injury.

AB - The possible role of endogenous opioids in the pathophysiology of spinal cord injury was evaluated utilizing a variety of experimental models and species. In the cat, we have shown that β-endorphin-like immunoreactivity was increased in plasma following traumatic spinal injury; such injury was associated with a decrease in spinal cord blood flow (SCBF) which was reversed by the opiate receptor antagonist naloxone. Naloxone treatment also significantly improved functional neurological recovery after severe injury. Thyrotropin-releasing hormone (TRH), possibly through its "anti-endorphin" actions, was even more effective than naloxone in improving functional recovery in the cat. In a rat model, utilizing a similar trauma method, TRH proved superior to naloxone in improving SCBF after injury. In addition, naloxone at high doses attenuated the hindlimb paralysis produced by temporary aortic occlusion in the rabbit. The high doses of naloxone required to improve neurological function after spinal injury suggest that naloxone's actions, if opiate receptor mediated, may be mediated by non-μ receptors. Dynorphin, an endogenous opioid with a high affinity for the κ receptor, produced hindlimb paralysis following intrathecal administration in rats. Taken together, these findings suggest that endogenous opioids, possibly acting at κ receptors in the spinal cord, may serve as pathophysiological factors in spinal cord injury.

KW - Dynorphin

KW - Endogenous opioids

KW - Naloxone

KW - Spinal cord injury

KW - TRH

UR - http://www.scopus.com/inward/record.url?scp=0021046777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021046777&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(83)90009-8

DO - 10.1016/0196-9781(83)90009-8

M3 - Article

VL - 4

SP - 631

EP - 634

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 5

ER -